Dare Bioscience reports FY2024 cash $15.7M, plans Sildenafil Cream 503B launch in Q4 2025

Dare Bioscience, Inc.

2025-Q1 EPS reported -$0.50 revenue$25,427

Cash and equivalents $15.7M at Dec 31, 2024; working capital deficit of $3.2M.
G&A expenses $9.2M (down 24% YoY); R&D expenses $14.2M (down 34% YoY).
Plans to make proprietary Sildenafil Cream 3.6% available via 503B compounding in Q4 2025; expects revenue and cash flow from Q4.
Ovaprene Phase 3 contraceptive study ongoing; half of 125 participants to complete ~6 months by Q2 2025 for interim DSMB review.
DARE-LARC1 received $3.5M grant in 2024; total $31.8M of up to $49M foundation grant received to date.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.